Ubs Asset Management Americas Inc Cellectis S.A. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Cellectis S.A. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,438,255 shares of CLLS stock, worth $2.26 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,438,255
Previous 1,438,255
-0.0%
Holding current value
$2.26 Million
Previous $3.05 Million
15.12%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CLLS
# of Institutions
33Shares Held
13.5MCall Options Held
5.9KPut Options Held
1.4K-
Long Focus Capital Management, LLC San Juan, PR4.62MShares$7.25 Million0.28% of portfolio
-
B Group, Inc. Dallas, TX3.08MShares$4.84 Million3.39% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$2.9 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.26 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny535KShares$839,2450.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $71.5M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...